



BioAlliance Pharma announces extension of Loramyc[®] approval in 13 European countries

It is bringing total European approvals to 26 European countries

Paris, March 25 2010 – BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, announced today the approval of Loramyc[®] in 13 additional European countries* through a Mutual Recognition Procedure with France as reference member state.

With this approval to a total of 26 European countries for Loramyc[®] and the recent Setofilm[®]** approval in 16 European countries, BioAlliance is building an attractive cancer supportive care portfolio including this two complementary products.

“These remarkable achievements for both Loramyc[®] and Setofilm[®] demonstrate BioAlliance Pharma’s expertise and the dedication of its teams. They will contribute to our commercial success in Europe”, said Dominique Costantini, President and CEO of BioAlliance Pharma.

** Recent Loramyc[®] approvals: Austria, Bulgaria, Czech Republic, Estonia, Greece, Hungary, Letonia, Lithuania, Poland, Portugal, Romania, Slovak Republic, Slovenia.*

Initial Loramyc[®] approvals: Belgium, Germany, Denmark, Finland, France, Italy, Luxemburg, Netherlands, Norway, Spain, Sweden, Switzerland, United Kingdom.

***Setofilm[®]: Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxemburg, Netherlands, Norway, Portugal, Spain, Sweden, UK.*

About BioAlliance Pharma

As a preferred partner for hospital-based specialists, BioAlliance Pharma is a company which develops and markets innovative products in France, especially in the fields of opportunistic infections and chemotherapy complications. In areas where medical needs are insufficiently met, our targeted approaches help overcome drug resistance and improve patient health & quality of life. BioAlliance Pharma’s ambition is to become a leading player in these fields by coupling innovation to patient needs.

For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2008 Reference Document filed with the AMF on April 7, 2009, which is available on the AMF website (<http://www.amf-france.org>) or on BioAlliance Pharma SA's website (<http://www.bioalliancepharma.com>).

BioAlliance Pharma SA

Dominique Costantini, President and CEO

Tel.: +33 1 45 58 76 01

dominique.costantini@bioalliancepharma.com

Nicolas Fellmann, CFO

Tel.: +33 1 45 58 71 00

nicolas.fellmann@bioalliancepharma.com

ALIZE RP

Caroline Carmagnol

Tel.: +33 6 64 18 99 59 / caroline@alizerp.com